Horizon Pharma plc Prices Offering of $350 Million of 2.50% Exchangeable Senior Notes - Seite 2

The exchange rate will initially be 34.8979 ordinary shares of Horizon Pharma plc per $1,000 principal amount of the notes (equivalent to an initial exchange price of approximately $28.66 per ordinary share of Horizon Pharma plc). The exchange rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or upon a tax redemption, the Issuer will increase the exchange rate for a holder who elects to exchange its notes in connection with such a corporate event or during the related redemption period in certain circumstances.

Morgan Stanley, Jefferies, Cowen and Company, Guggenheim Securities and UBS Investment Bank are acting as joint book-running managers of the offering. JMP Securities and Avondale Partners are acting as co-managers.

None of the notes, any of Horizon Pharma plc's ordinary shares issuable upon exchange of the notes or the guarantee have been or are expected to be registered under the Securities Act or under any state securities laws and, unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Horizon Pharma plc

Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. Horizon's U.S. marketed products are ACTIMMUNE^® (interferon gamma-1b), DUEXIS^® (ibuprofen/famotidine), PENNSAID^® (diclofenac sodium topical solution) 2% w/w, RAYOS^® (prednisone) delayed-release tablets and VIMOVO^® (naproxen/esomeprazole magnesium). Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com.